TNF and cancer: Specifically, since miRNA-based combinatorial cancer therapy has shown some promise in oncology, it is likely that a similar combinatorial approach—miRNA therapeutics, together with existing therapeutics, such as aminosalicylates, anti-TNFα inhibitors, corticosteroids, and newer biologic therapies (Vedolizumab and Ustekinumab)—might be beneficial for the prevention of IBD, as well as to avoid recurrence or the loss of response to current therapies.